Rx Product News (December 2018)

DECEMBER 20, 2018

LUCEMYRA

MANUFACTURED BY: Salix Pharmaceuticals Inc and US WorldMeds LLC
INDICATION: Salix Pharmaceuticals and US WorldMeds have collaborated to launch Lucemyra (lofexidine), a nonopioid indicated to alleviate withdrawal symptoms when opioids are abruptly discontinued. Withdrawal symptoms are a primary reason that people do not discontinue opioid use, and relieving these symptoms may help reduce opioid addiction and overdoses in the United States, according to US WorldMeds. A co-pay program allows patients to receive Lucemyra for as little as $25.
DOSAGE FORM: Oral tablet
FOR MORE INFORMATION: lucemyra.com


ILUMETRI
MANUFACTURED BY: Almirall, Sun Pharma
INDICATION: Almirall has received approval from the European Commission for Ilumetri (tildrakizumab) for the treatment of plaque psoriasis. The newly approved drug is indicated to treat moderate to severe chronic plaque psoriasis in adults who are eligible for systemic therapy. Sun Pharma, the manufacturer of Ilumetri, has out-licensed the medication to Almirall so that the product can be commercialized in Europe. Ilumetri proved to have minimal adverse effects and was typically well tolerated in clinical trials. The treatment is convenient, with just 4 doses per year once psoriasis is under control.
DOSAGE FORM: Injection
FOR MORE INFORMATION: sunpharma.com


AJOVY 
MANUFACTURED BY: Teva Pharmaceuticals
INDICATION: The FDA has approved Ajovy (fremanezumab-vfrm) as a preventive treatment for adults who suffer migraines. The newly approved drug works by inhibiting the activity of calcitonin gene-related peptide, 1 of the molecules responsible for causing migraine headaches. Patients can receive a 225-mg injection monthly or receive 3 consecutive 225-mg injections (675 mg) every 3 months. 
DOSAGE FORM: Injection
FOR MORE INFORMATION: tevapharm.com


LUMOXITI
MANUFACTURED BY: AstraZeneca
INDICATION: The FDA has approved Lumoxiti (moxetumomab pasudotox-tdfk) to treat adults with relapsed/refractory hairy cell leukemia (HCL) who have previously received 2 systemic therapies, such as purine nucleoside analogue. The recently approved injection is the first CD22-directed cytotoxin indicated to treat patients with HCL.
DOSAGE FORM: Injection
FOR MORE INFORMATION: astrazeneca.com

 

SHARE THIS
1